drugset / Trial / NCT06416709

Stem Cell Treatment for Lung Injury Caused by Major Infectious Diseases

NCT06416709

RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for Lung injury caused by major infectious diseases.

Timeline

Start
2023-05-10
Primary completion
2026-05-10
Completion
2026-05-10

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy 5e+07 cells Intravenous

Indications